Instant Assessment: How Mature is Your Health System’s Unsaleable Returns Program?

Learn how McKesson’s Rapid Returns Solution can help improve your unsaleable returns program.

By McKesson Health Systems Editorial Team

Date

March 14, 2024

Read time: 2 minutes

By: McKesson Health Systems Editorial Team

The McKesson Rapid Returns Solution (MRRS), which is also available to health system customers as an on-site model, helps you maximize credit for returned pharmaceuticals and OTC products, credits you faster, and simplifies the returns process so you gain more time for your patients. With MRRS, intended for McKesson-purchased items only, you send one no-cost shipment to one processor. McKesson pays for shipping, processing, and destruction, safeguarding for safe, responsible handling and disposal of un-used drugs. The solution makes it simple to return items, such as:

Unsaleable controlled substances (II-V)
Unsaleable pharmaceuticals with six months or less remaining shelf life
Unsaleable over-the-counter products with three months or less remaining shelf life
Unsaleable recalled products

The credit you earn is applied to your McKesson account 30 days after your return is processed, reducing your overall costs and improving your bottom line.

To learn more about how McKesson’s Rapid Returns Solution may help improve your current unsaleable returns program, take this instant assessment now.

Additional information is available in the MRRS brochure, available here for instant download (PDF, 168 KB).

Subscribe to our monthly Prescribed Perspectives newsletter today to have our exclusive content delivered directly to your inbox!

Brittany Ulrich, PharmD, CSP, BCBBS, examines how limited distribution drugs and payer requirements push specialty prescriptions outside the organization, eroding visibility into patient outcomes, and how Biologics by McKesson helps health systems expect more when it comes to maintaining care continuity.

Aerial view of a large warehouse complex with loading docks, trucks and intersecting roads.

Case Study: How McKesson’s Winter-Storm Playbook Kept Specialty Drugs Moving

Expect more for the business of pharmacy with a pressure-tested, multi-layered business continuity strategy.

Researcher in a laboratory looks through shelving lined with containers and supplies.

What You Should Know About the CMS Proposed 340B Payment Change

Dr. Andrew Wilson, B.S., Pharm.D., FASHP, reflects on the proposed CY 2027 OPPS rule for several outpatient drugs purchased through the 340B program, and the next phase of specialty drug margin management for the business of pharmacy.

Open laptop beside a stack of tabbed documents in a binder on a desk, with a softly blurred office background.

Top Prescribed Perspectives Reads for August

The top three Prescribed Perspectives articles most read by health systems in August.

Business professionals greet with a handshake in a modern office while colleagues stand nearby during a networking conversation.

Upcoming Event: inSPire 2026

Connect with McKesson at inSPire to help shape the future of specialty pharmacy

Healthcare professional and colleague review information on a tablet in a clinical setting.

Where Does Your Health System Fall on the Specialty and Infusion Growth Journey?

With our assessment, benchmark your progress across the specialty and infusion journey to achieve more for the business of pharmacy.

Instant Assessment: How Mature is Your Health System’s Unsaleable Returns Program?

Related Stories

Related Tags